BioStock: Immunicum finalises phase I ILIAD trial
Immunicum’s phase Ib ILIAD project was designed to evaluate ilixadencel across a broad range of cancer indications and in combination with the anti-PD1 checkpoint inhibitor pembrolizumab. The company has announced completing the project after conducting a positive safety and response evaluation, and Immunicum has decided not to pursue a phase II portion of the trial. BioStock spoke with CEO Erik Manting to learn more about the results and the decision-making around phase II.Read the interview with Immunicum's CEO Erik Manting at biostock.se: https://www.biostock.se/en/2021/12/immunicum-